Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,262.56 89.32 0.55%
S&P 500 1,842.98 12.37 0.68%
NASDAQ 4,034.16 11.47 0.29%
Ticker Volume Price Price Delta
STOXX 50 3,091.52 -40.05 -1.28%
FTSE 100 6,541.61 -42.15 -0.64%
DAX 9,173.71 -165.46 -1.77%
Ticker Volume Price Price Delta
NIKKEI 14,371.51 374.70 2.68%
TOPIX 1,162.48 26.39 2.32%
HANG SENG 22,820.67 149.41 0.66%

Advanced Cell Technology Announces Settlement of Litigation



  Advanced Cell Technology Announces Settlement of Litigation

     Agreement Resolves All Litigation Associated with Previously Issued
                            Convertible Debentures

Business Wire

MARLBOROUGH, Mass. -- January 17, 2013

Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC or the “Company”), a leader
in the field of regenerative medicine, today announced that it has reached a
settlement agreement with CAMOFI and CAMZHN Master LDC (collectively, the
“Investors”) resolving a lawsuit filed against ACT in the Supreme Court of New
York relating to the conversion price of certain notes and the exercise price
of certain warrants. The Investors claimed that the conversion price for the
debentures and warrants they held should have been adjusted as a result of a
transaction entered into between the Company’s previous management and an
investor in 2010. At the time, the Investors had not converted most of their
debentures or warrants. The Investors were the final parties to settle the
litigation, which had previously been disclosed in multiple ACT 8-K filings.

Under the terms of the settlement, ACT will pay $12.5 million to the
Investors, plus legal expenses, comprised of $2 million in cash, $4.5 million
in restricted common stock and $6 million through the issuance of an 8%
amortizing redeemable convertible debenture that matures June, 2015. The
Company and Investors have agreed to enter into a registration rights
agreement, which will require the Company to register the shares of common
stock into which the debentures are convertible with the Securities and
Exchange Commission.

“This settlement ends the cost and uncertainty associated with this litigation
and resolves all of the litigation relating to the debentures, which have
represented an ongoing cost and distraction for both management and our
shareholders,” said Gary Rabin, chairman and CEO of ACT. “The resolution of
this litigation represents a significant step in resolving past potential
liabilities and in enhancing the Company’s ability to attract a broader
shareholder base.”

Further details are available in the Company’s Form 8-K filed with the
Securities and Exchange Commission.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., is a biotechnology company applying cellular
technology in the field of regenerative medicine. For more information, visit
www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating
results, future growth in research and development programs, potential
applications of our technology, opportunities for the company and any other
statements about the future expectations, beliefs, goals, plans, or prospects
expressed by management constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any
statements that are not statements of historical fact (including statements
containing the words “will,” “believes,” “plans,” “anticipates,” “expects,”
“estimates,” and similar expressions) should also be considered to be
forward-looking statements. There are a number of important factors that could
cause actual results or events to differ materially from those indicated by
such forward-looking statements, including: limited operating history, need
for future capital, risks inherent in the development and commercialization of
potential products, protection of our intellectual property, and economic
conditions generally. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed from time to
time in the company’s periodic reports, including the report on Form 10-K for
the year ended December 31, 2011. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company’s management at the time
they are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company’s management at the time
they are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change. There can be no assurance that the Company’s
clinical trials will be successful.

Contact:

Investors:
CEOcast, Inc.
James Young, 212-732-4300
or
Press:
ACT Corporate Communications
Bill Douglass, 646-450-3615
or:
Russo Partners
Martina Schwarzkopf, Ph.D., 212-845-4292
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement